Indication
Indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Medicine details
- Medicine name:
- delta-9-tetrahydrocannabinol and cannabidiol (Sativex)
- SMC ID:
- SMC2473
- Pharmaceutical company
- GW Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Publication due date:
- 12 September 2022
- SMC meeting date:
- 02 August 2022
- Patient group submission deadline:
- 04 July 2022